Clinical medicine profile
Aceclofenac / Paracetamol
NSAID + paracetamol combination
- Route
- ORAL / RECTAL / IV
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Aceclofenac] Active peptic ulcer / GI bleeding.
- Severe heart failure.
- NSAID-exacerbated respiratory disease (aspirin-sensitive asthma) for non-selective agents.
- Third trimester pregnancy (ductus arteriosus, oligohydramnios — class warning).
- Severe renal impairment for many agents.
- Hypersensitivity to NSAIDs. [Paracetamol] Severe active hepatic disease / acute liver failure.
- Hypersensitivity.
- Chronic heavy alcohol use — use reduced maximum daily dose or avoid.
Precautions
- [From component Paracetamol] Risk of severe hepatotoxicity in overdose.
- Chronic high-dose use, malnutrition, enzyme-inducing drugs, and alcohol increase risk.
- Check total daily intake from all sources.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Usually not children.
Avoid significant RI.
- CrCl 0–120: See renal_dose_adjustment; confirm product SmPC.
Avoid active liver disease.
Use, effects & interactions
Indications
- Short-term pain/inflammation when combo product used.
- Clinical selection for Aceclofenac / Paracetamol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: NSAID + paracetamol combination.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- [Aceclofenac] Dyspepsia, nausea, fluid retention, raised BP.
- Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare). [Paracetamol] Rare at therapeutic doses.
- Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).
Drug interactions
Open multi-drug checker ↗- Alphabetical A-series MyDrugIndex generic monograph.
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Paracetamol.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Inhibitors of cyclo-oxygenase [COX-1 and COX-2] enzyme that catalyzes the conversion of arachidonic acid to PGH2.
Read complete mechanism
Inhibitors of cyclo-oxygenase [COX-1 and COX-2] enzyme that catalyzes the conversion of arachidonic acid to PGH2. Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways. Antipyretic effect via hypothalamic heat-regulating centre. Minimal peripheral anti-inflammatory action.
30–60 minutes oral
4–6 hours
ORAL / RECTAL / IV
(glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted.
~2–3 h; prolonged in liver disease/overdose.
Pregnancy, lactation & diet
[Aceclofenac] Avoid in third trimester. Earlier pregnancy: use only if needed; prefer paracetamol first-line. [Paracetamol] Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.
Compatible with breastfeeding at standard doses.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| ACEPAR CAPS 10`S | Not recorded | — | KES 186.90Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| ACEPAR MR 10*S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| ACEPAR SP TABS 10*S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| ACP-MR TABS 10*S | Not recorded | — | KES 160.17Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| ACP CAPS 30*S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| ACP SP TABS 10*S | Not recorded | — | KES 203.17Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| ACP TH8 TABS 10`S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| Ceclonec-p | Afya Index product / manufacturer unverified | mg/ 500mg 10's | Unavailable |
| LYSODOL P | DAIMA BIASHARA / Wholesale Import | — | KES 172.00daima_biashara_price_list |
| Zerodol-p | IPCA | mg / 500mg 30's | Unavailable |
| ZYRTAL PLUS 100/1000 | PHARMAKEN LTD | Tablet | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.